Diana O Perkins Selected Research

Antipsychotic Agents (Antipsychotics)

1/2022	Mismatch Negativity in Response to Auditory Deviance and Risk for Future Psychosis in Youth at Clinical High Risk for Psychosis.
1/2020	Predictive validity of conversion from the clinical high risk syndrome to frank psychosis.
1/2019	Enhancing the Treatment of Patients With Schizophrenia Through Continuous Care.
1/2019	Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium.
12/2018	The relation of atypical antipsychotic use and stress with weight in individuals at clinical high risk for psychosis.
11/2017	Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics?
8/2014	A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
8/2013	Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011.
2/2011	Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.
11/2009	The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Diana O Perkins Research Topics

Disease

45	Psychotic Disorders (Schizoaffective Disorder) 01/2022 - 01/2005
36	Schizophrenia (Dementia Praecox) 01/2022 - 12/2002
10	Weight Gain 12/2018 - 12/2002
7	Prodromal Symptoms 01/2020 - 08/2003
3	Mental Disorders (Mental Disorder) 01/2020 - 08/2013
2	Substance-Related Disorders (Drug Abuse) 01/2020 - 01/2009
2	Inflammation (Inflammations) 01/2017 - 03/2015
2	Hypertension (High Blood Pressure) 08/2015 - 08/2014
2	Weight Loss (Weight Reduction) 09/2011 - 09/2005
2	Body Weight (Weight, Body) 06/2009 - 01/2005
1	Neurodevelopmental Disorders 01/2022
1	Cerebral Cortical Thinning 10/2017
1	Atherosclerosis 01/2017
1	Obesity 08/2014
1	Treatment-Resistant Schizophrenia 08/2014
1	Dyslipidemias (Dyslipidemia) 08/2014
1	Type 2 Diabetes Mellitus (MODY) 08/2014
1	Mood Disorders (Mood Disorder) 08/2014
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 06/2009
1	Disease Progression 05/2009
1	Sleep Initiation and Maintenance Disorders (Insomnia) 07/2007
1	Menstruation Disturbances 07/2007
1	Tardive Dyskinesia 12/2006
1	Eosinophilia 04/2006
1	Agranulocytosis (Granulocytopenia) 04/2006
1	Insulin Resistance 01/2005
1	Psychomotor Agitation (Akathisia) 12/2002

Drug/Important Bio-Agent (IBA)

31	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 12/2002
18	Olanzapine (Zyprexa)FDA Link 09/2011 - 08/2003
10	Risperidone (Risperdal Consta)FDA LinkGeneric 09/2011 - 04/2006
9	Quetiapine Fumarate (Seroquel)FDA Link 09/2011 - 04/2006
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2013
5	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2021 - 09/2013
4	Pharmaceutical PreparationsIBA 01/2020 - 05/2003
4	Perphenazine (Trilafon)FDA LinkGeneric 11/2009 - 09/2005
3	Polytetrafluoroethylene (Teflon)FDA Link 01/2022 - 05/2010
3	Biological ProductsIBA 01/2021 - 06/2006
3	CytokinesIBA 01/2019 - 10/2017
3	LipidsIBA 08/2015 - 01/2005
3	Glucose (Dextrose)FDA LinkGeneric 06/2009 - 01/2005
3	ziprasidone (Geodon)FDA Link 06/2007 - 04/2006
2	MicroRNAs (MicroRNA)IBA 10/2017 - 01/2007
2	Clozapine (Clozaril)FDA LinkGeneric 08/2014 - 04/2006
2	Triglycerides (Triacylglycerol)IBA 09/2011 - 01/2005
2	Indicators and Reagents (Reagents)IBA 02/2011 - 01/2011
2	Haloperidol (Haldol)FDA LinkGeneric 05/2009 - 12/2005
1	Sp4 Transcription FactorIBA 01/2022
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2022
1	Silver Sulfadiazine (SSD)FDA LinkGeneric 01/2021
1	gamma-Aminobutyric Acid (GABA)IBA 01/2020
1	ParvalbuminsIBA 01/2020
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2020
1	Glutathione (Reduced Glutathione)IBA 01/2020
1	Metalloproteases (Metalloproteinases)IBA 01/2020
1	SmokeIBA 10/2019
1	antineoplaston A10 (A 10)IBA 04/2019
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2019
1	Blood Proteins (Serum Proteins)IBA 01/2018
1	Lysine (L-Lysine)FDA Link 01/2017
1	Formaldehyde (Formol)FDA Link 01/2017
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2017
1	Malondialdehyde (Propanedial)IBA 01/2017
1	Peroxidase (Myeloperoxidase)IBA 01/2017
1	Hormones (Hormone)IBA 03/2015
1	Prednisolone (Predate)FDA LinkGeneric 03/2013
1	Gonadal HormonesIBA 03/2013
1	RNA (Ribonucleic Acid)IBA 12/2012
1	DNA (Deoxyribonucleic Acid)IBA 12/2012
1	ElementsIBA 10/2012
1	HDL LipoproteinsIBA 09/2011
1	HDL CholesterolIBA 09/2011
1	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 07/2010
1	Antidepressive Agents (Antidepressants)IBA 11/2009
1	Neuregulin-1 (Neuregulin 1)IBA 10/2008
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 12/2006
1	Amantadine (Aman)FDA LinkGeneric 09/2005
1	Insulin (Novolin)FDA Link 01/2005
1	LeptinIBA 01/2005

Therapy/Procedure

6	Therapeutics 01/2022 - 01/2005
2	Patient Readmission 01/2019 - 12/2002
2	Injections 01/2019 - 11/2017
1	Episode of Care 01/2021
1	Transcutaneous Electric Nerve Stimulation (TENS) 10/2020
1	Drug Therapy (Chemotherapy) 01/2020
1	Aftercare (After-Treatment) 03/2008